Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Neoplasms of the CNS

Free Subscription Articles published in BMC Cancer Retrieve available abstracts of 258 articles: HTML format

Single Articles

May 2024
1. WANG J, Wang G, Cheng L, Zhu H, et al
   Preoperative peripheral inflammatory markers are predictors of postoperative central diabetes insipidus in craniopharyngioma patients: a retrospective study.
   BMC Cancer. 2024;24:572.
   PubMed     Abstract available
   
   
   April 2024
2. KUMTHEKAR P, Lyleroehr M, Lacson L, Lukas RV, et al
   A qualitative evaluation of factors influencing Tumor Treating fields (TTFields) therapy decision making among brain tumor patients and physicians.
   BMC Cancer. 2024;24:527.
   PubMed     Abstract available
   
   
   
3. LIU C, Liu F, Nie D, Xiao Y, et al
   Gut microbiota composition and metabolic characteristics in patients with Craniopharyngioma.
   BMC Cancer. 2024;24:521.
   PubMed     Abstract available
   
   
   
4. DVORAKOVA K, Skarkova V, Vitovcova B, Soukup J, et al
   Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients.
   BMC Cancer. 2024;24:509.
   PubMed     Abstract available
   
   
   
5. SHI MX, Ding X, Tang L, Cao WJ, et al
   PROTAC EZH2 degrader-1 overcomes the resistance of podophyllotoxin derivatives in refractory small cell lung cancer with leptomeningeal metastasis.
   BMC Cancer. 2024;24:504.
   PubMed     Abstract available
   
   
   
6. ORESKOVIC D, Madero Pohlen A, Cvitkovic I, Alen JF, et al
   Chronic hyperglycemia and intracranial meningiomas.
   BMC Cancer. 2024;24:488.
   PubMed     Abstract available
   
   
   
7. DENG MY, da Silva AS, Goller PC, Konig L, et al
   Plasma extracellular vesicles in meningioma patients following radiotherapy as liquid biopsy- a prospective explorative biomarker study (ARO 2023-05/AG-NRO-07).
   BMC Cancer. 2024;24:449.
   PubMed     Abstract available
   
   
   
8. KONG C, Yin X, Zou J, Ma C, et al
   The application of different machine learning models based on PET/CT images and EGFR in predicting brain metastasis of adenocarcinoma of the lung.
   BMC Cancer. 2024;24:454.
   PubMed     Abstract available
   
   
   
9. CHEN M, Li R, Kong Y, Shi L, et al
   Rational and design of prophylactic cranial irradiation (PCI) and brain MRI surveillance versus brain MRI surveillance alone in patients with limited-stage small cell lung cancer achieving complete remission (CR) of tumor after chemoradiotherapy: a mu
   BMC Cancer. 2024;24:429.
   PubMed     Abstract available
   
   
   March 2024
10. WANG G, Ren X, Li J, Cui R, et al
    High expression of RTEL1 predicates worse progression in gliomas and promotes tumorigenesis through JNK/ELK1 cascade.
    BMC Cancer. 2024;24:385.
    PubMed     Abstract available
    
    
    
11. ZHANG W, Blank A, Kremenetskaia I, Nitzsche A, et al
    CD13 expression affects glioma patient survival and influences key functions of human glioblastoma cell lines in vitro.
    BMC Cancer. 2024;24:369.
    PubMed     Abstract available
    
    
    
12. QI H, Hou Y, Zheng Z, Zheng M, et al
    Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
    BMC Cancer. 2024;24:362.
    PubMed     Abstract available
    
    
    
13. MA Y, Gong Y, Qiu Q, Ma C, et al
    Research on multi-model imaging machine learning for distinguishing early hepatocellular carcinoma.
    BMC Cancer. 2024;24:363.
    PubMed     Abstract available
    
    
    
14. HUANG Y, Wu Z, Peng Z, Liu A, et al
    Hsa_circ_0004872 alleviates meningioma progression by sponging miR-190a-3p/PTEN signaling.
    BMC Cancer. 2024;24:345.
    PubMed     Abstract available
    
    
    
15. ROUTMAN DM, Jusue-Torres I, Brown PD, Trifiletti DM, et al
    Pre-operative vs. post-operative stereotactic radiosurgery for operative metastatic brain tumors: study protocol for a phase III clinical trial.
    BMC Cancer. 2024;24:332.
    PubMed     Abstract available
    
    
    
16. MENG J, Qian W, Yang Z, Gong L, et al
    p53/E2F7 axis promotes temozolomide chemoresistance in glioblastoma multiforme.
    BMC Cancer. 2024;24:317.
    PubMed     Abstract available
    
    
    February 2024
17. SUN L, Jin X, Xie L, Xu G, et al
    Retraction Note: Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression.
    BMC Cancer. 2024;24:275.
    PubMed    
    
    
    
18. QIAO W, Wang Y, Luo C, Wu J, et al
    Development of preoperative and postoperative models to predict recurrence in postoperative glioma patients: a longitudinal cohort study.
    BMC Cancer. 2024;24:274.
    PubMed     Abstract available
    
    
    
19. KINO S, Kanamori M, Shimoda Y, Niizuma K, et al
    Distinguishing IDH mutation status in gliomas using FTIR-ATR spectra of peripheral blood plasma indicating clear traces of protein amyloid aggregation.
    BMC Cancer. 2024;24:222.
    PubMed     Abstract available
    
    
    
20. BEN-ZION BERLINER M, Yust-Katz S, Lavie I, Goldberg Y, et al
    Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.
    BMC Cancer. 2024;24:219.
    PubMed     Abstract available
    
    
    
21. LI G, Ma L, Feng C, Yin H, et al
    MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma.
    BMC Cancer. 2024;24:220.
    PubMed     Abstract available
    
    
    
22. BOCCACINO JM, Dos Santos Peixoto R, Fernandes CFL, Cangiano G, et al
    Integrated transcriptomics uncovers an enhanced association between the prion protein gene expression and vesicle dynamics signatures in glioblastomas.
    BMC Cancer. 2024;24:199.
    PubMed     Abstract available
    
    
    
23. SHIM YB, Oh BC, Lee EK, Park MH, et al
    Comparison of partitioned survival modeling with state transition modeling approaches with or without consideration of brain metastasis: a case study of Osimertinib versus pemetrexed-platinum.
    BMC Cancer. 2024;24:189.
    PubMed     Abstract available
    
    
    
24. PHAM CP, Nguyen TTH, Do AT, Nguyen TK, et al
    A real-world cohort study of first-line afatinib in patients with EGFR-mutant advanced non-small cell lung cancer in Vietnam.
    BMC Cancer. 2024;24:176.
    PubMed     Abstract available
    
    
    
25. LIAO L, Tang J, Hong Z, Jiang W, et al
    The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study.
    BMC Cancer. 2024;24:164.
    PubMed     Abstract available
    
    
    January 2024
26. ZHANG X, Li Y, Zhang G, Ma C, et al
    Temporal trend in hospitalizations for malignant neoplasm and benign neoplasm: a nationwide study, China, 2004-2020.
    BMC Cancer. 2024;24:154.
    PubMed     Abstract available
    
    
    
27. VAN TILBURG CM, Kilburn LB, Perreault S, Schmidt R, et al
    LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration.
    BMC Cancer. 2024;24:147.
    PubMed     Abstract available
    
    
    
28. YU W, Zhou M, Niu H, Li J, et al
    Prognostic marker CXCL5 in glioblastoma polyformis and its mechanism of immune invasion.
    BMC Cancer. 2024;24:140.
    PubMed     Abstract available
    
    
    
29. YAO B, Wang H, Wu X, Wang C, et al
    A system review of central nervous system tumors on children in China: epidemiology and clinical characteristics.
    BMC Cancer. 2024;24:138.
    PubMed     Abstract available
    
    
    
30. HEUER S, Burghaus I, Gose M, Kessler T, et al
    PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma.
    BMC Cancer. 2024;24:135.
    PubMed     Abstract available
    
    
    
31. LU Y, Liao L, Du K, Mo J, et al
    Clinical activity and safety of sintilimab, bevacizumab, and TMZ in patients with recurrent glioblastoma.
    BMC Cancer. 2024;24:133.
    PubMed     Abstract available
    
    
    
32. LIU JS, Cai YX, He YZ, Xu J, et al
    Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
    BMC Cancer. 2024;24:123.
    PubMed     Abstract available
    
    
    
33. QIAN J, He Z, Wu Y, Li H, et al
    Analysis of the efficacy of upfront brain radiotherapy versus deferred radiotherapy for EGFR/ALK-positive non-small cell lung cancer with brain metastases: a retrospective study.
    BMC Cancer. 2024;24:117.
    PubMed     Abstract available
    
    
    
34. YANG W, Han Y, He C, Zhong S, et al
    Association between psychiatric disorders and glioma risk: evidence from Mendelian randomization analysis.
    BMC Cancer. 2024;24:118.
    PubMed     Abstract available
    
    
    
35. ZHU X, Liu Y, Guo W, Liang Q, et al
    Epidemiology, characteristics, and prognostic factors of lymphoplasmacyte-rich meningioma: a systematic literature review.
    BMC Cancer. 2024;24:110.
    PubMed     Abstract available
    
    
    
36. LI L, Xia S, Zhao Z, Deng L, et al
    EMP3 as a prognostic biomarker correlates with EMT in GBM.
    BMC Cancer. 2024;24:89.
    PubMed     Abstract available
    
    
    
37. ZUCHEGNA C, Leone S, Romano A, Porcellini A, et al
    KRAS is a molecular determinant of platinum responsiveness in glioblastoma.
    BMC Cancer. 2024;24:77.
    PubMed     Abstract available
    
    
    
38. MASTALL M, Roth P, Bink A, Fischer Maranta A, et al
    A phase Ib/II randomized, open-label drug repurposing trial of glutamate signaling inhibitors in combination with chemoradiotherapy in patients with newly diagnosed glioblastoma: the GLUGLIO trial protocol.
    BMC Cancer. 2024;24:82.
    PubMed     Abstract available
    
    
    
39. BHASKARAN D, Savage J, Patel A, Collinson F, et al
    A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial.
    BMC Cancer. 2024;24:83.
    PubMed     Abstract available
    
    
    
40. HUANG CY, Bai MH, Shen JW, Sun QQ, et al
    Anus preservation in low rectal adenocarcinoma based on MMR/MSI status (APRAM): a study protocol for a randomised, controlled, open-label, multicentre phase III trial.
    BMC Cancer. 2024;24:57.
    PubMed     Abstract available
    
    
    
41. SUN Y, Liu P, Wang Z, Zhang H, et al
    Efficacy and indications of gamma knife radiosurgery for recurrent low-and high-grade glioma.
    BMC Cancer. 2024;24:37.
    PubMed     Abstract available
    
    
    
42. CRUCITTA S, Pasqualetti F, Gonnelli A, Ruglioni M, et al
    IDH1 mutation is detectable in plasma cell-free DNA and is associated with survival outcome in glioma patients.
    BMC Cancer. 2024;24:31.
    PubMed     Abstract available
    
    
    
43. MOHAJERANI F, Tehrankhah ZM, Rahmani S, Afsordeh N, et al
    CLEC19A overexpression inhibits tumor cell proliferation/migration and promotes apoptosis concomitant suppression of PI3K/AKT/NF-kappaB signaling pathway in glioblastoma multiforme.
    BMC Cancer. 2024;24:19.
    PubMed     Abstract available
    
    
    
44. OUDIN A, Moreno-Sanchez PM, Baus V, Niclou SP, et al
    Magnetic resonance imaging-guided intracranial resection of glioblastoma tumors in patient-derived orthotopic xenografts leads to clinically relevant tumor recurrence.
    BMC Cancer. 2024;24:3.
    PubMed     Abstract available
    
    
    
45. ZHAO S, Zhang M, Zhang Q, Wu J, et al
    Anlotinib alone or in combination with bevacizumab in the treatment of recurrent high-grade glioma: a prospective single-arm, open-label phase II trial.
    BMC Cancer. 2024;24:6.
    PubMed     Abstract available
    
    
    December 2023
46. DAI L, Zhou P, Lyu L, Jiang S, et al
    Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
    BMC Cancer. 2023;23:1249.
    PubMed     Abstract available
    
    
    
47. ZHANG K, Zhang T, Guo Z, Zhao F, et al
    Adding simultaneous integrated boost to whole brain radiation therapy improved intracranial tumour control and minimize radiation-induced brain injury risk for the treatment of brain metastases.
    BMC Cancer. 2023;23:1240.
    PubMed     Abstract available
    
    
    
48. ADEGBOYEGA B, Joseph A, Alabi A, Omomila J, et al
    Patient reported outcomes following whole brain radiotherapy in patients with brain metastases in NSIA-LUTH Cancer Center.
    BMC Cancer. 2023;23:1233.
    PubMed     Abstract available
    
    
    
49. BAI J, He M, Gao E, Yang G, et al
    Radiomic texture analysis based on neurite orientation dispersion and density imaging to differentiate glioblastoma from solitary brain metastasis.
    BMC Cancer. 2023;23:1231.
    PubMed     Abstract available
    
    
    November 2023
50. SENRUNG A, Tripathi T, Yadav J, Janjua D, et al
    In vivo antiangiogenic effect of nimbolide, trans-chalcone and piperine for use against glioblastoma.
    BMC Cancer. 2023;23:1173.
    PubMed     Abstract available
    
    
    
51. ZHANG Y, Wu X, Zhu J, Lu R, et al
    Knockdown of SLC39A14 inhibits glioma progression by promoting erastin-induced ferroptosis SLC39A14 knockdown inhibits glioma progression.
    BMC Cancer. 2023;23:1120.
    PubMed     Abstract available
    
    
    October 2023
52. SONG Y, Lin S, Chen J, Dang J, et al
    First-line treatment with TKI plus brain radiotherapy versus TKI alone in EGFR-mutated non-small cell Lung cancer with brain metastases: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1043.
    PubMed     Abstract available
    
    
    
53. WEI D, Niu B, Zhai B, Liu XB, et al
    Expression profiles and function prediction of tRNA-derived fragments in glioma.
    BMC Cancer. 2023;23:1015.
    PubMed     Abstract available
    
    
    
54. YANG XS, Zhu P, Xie RX, Chen PF, et al
    Tracking tumor alteration in glioma through serum fibroblast activation protein combined with image.
    BMC Cancer. 2023;23:1012.
    PubMed     Abstract available
    
    
    
55. ROZATI H, Chen J, Williams M
    Overall survival following stereotactic radiosurgery for ten or more brain metastases: a systematic review and meta-analysis.
    BMC Cancer. 2023;23:1004.
    PubMed     Abstract available
    
    
    
56. WANG Z, Cui Y, Wang F, Xu L, et al
    DNA methylation-regulated LINC02587 inhibits ferroptosis and promotes the progression of glioma cells through the CoQ-FSP1 pathway.
    BMC Cancer. 2023;23:989.
    PubMed     Abstract available
    
    
    
57. VINCENT CA, Nissen I, Dakhel S, Hornblad A, et al
    Epigenomic perturbation of novel EGFR enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomide.
    BMC Cancer. 2023;23:945.
    PubMed     Abstract available
    
    
    
58. ROBINSON SD, Samuels M, Jones W, Gilbert D, et al
    Shooting the messenger: a systematic review investigating extracellular vesicle isolation and characterisation methods and their influence on understanding extracellular vesicles-radiotherapy interactions in glioblastoma.
    BMC Cancer. 2023;23:939.
    PubMed     Abstract available
    
    
    
59. MING Y, Luo C, Ji B, Cheng J, et al
    ARPC5 acts as a potential prognostic biomarker that is associated with cell proliferation, migration and immune infiltrate in gliomas.
    BMC Cancer. 2023;23:937.
    PubMed     Abstract available
    
    
    September 2023
60. CHENG WY, Shen CC, Liang YJ, Chiao MT, et al
    Polymorphism at codon 31 of CDKN1A (p21) as a predictive factor for bevacizumab therapy in glioblastoma multiforme.
    BMC Cancer. 2023;23:886.
    PubMed     Abstract available
    
    
    
61. HATTORI EY, Arakawa Y, Mineharu Y, Furukawa K, et al
    Seizure control by adding on other anti-seizure medication on seizure during levetiracetam administration in patients with glioma-related epilepsy.
    BMC Cancer. 2023;23:849.
    PubMed     Abstract available
    
    
    
62. SHAN E, Cao YN, Zhang Y, Chen W, et al
    Integrated profiling identifies CACNG3 as a prognostic biomarker for patients with glioma.
    BMC Cancer. 2023;23:846.
    PubMed     Abstract available
    
    
    
63. LIU Z, Hong X, Wang L, Ma Z, et al
    Radiomic features from multiparametric magnetic resonance imaging predict molecular subgroups of pediatric low-grade gliomas.
    BMC Cancer. 2023;23:848.
    PubMed     Abstract available
    
    
    August 2023
64. MIRANDA J, Vazquez-Blomquist D, Bringas R, Fernandez-de-Cossio J, et al
    A co-formulation of interferons alpha2b and gamma distinctively targets cell cycle in the glioblastoma-derived cell line U-87MG.
    BMC Cancer. 2023;23:806.
    PubMed     Abstract available
    
    
    
65. TAN C, Wei J, Li Z, Tian N, et al
    Circ_0021350 plays an oncogene role by regulating miR-1207-3p/PIK3R3 in glioblastoma.
    BMC Cancer. 2023;23:808.
    PubMed     Abstract available
    
    
    
66. WANG X, Chen J, Lei Z, Chen H, et al
    Propensity score-matched analysis comparing hippocampus-avoidance whole-brain radiotherapy plus simultaneous integrated boost with hippocampus‑avoidance whole-brain radiotherapy alone for multiple brain metastases-a retrospective study in multiple i
    BMC Cancer. 2023;23:796.
    PubMed     Abstract available
    
    
    
67. NEUTEL CLG, Viozzi I, Overduin CG, Rijpma A, et al
    Study protocol for a multicenter randomised controlled trial on the (cost)effectiveness of biopsy combined with same-session MR-guided LITT versus biopsy alone in patients with primary irresectable glioblastoma (EMITT trial).
    BMC Cancer. 2023;23:788.
    PubMed     Abstract available
    
    
    
68. SOUSA N, Geiss C, Bindila L, Lieberwirth I, et al
    Targeting sphingolipid metabolism with the sphingosine kinase inhibitor SKI-II overcomes hypoxia-induced chemotherapy resistance in glioblastoma cells: effects on cell death, self-renewal, and invasion.
    BMC Cancer. 2023;23:762.
    PubMed     Abstract available
    
    
    
69. ZHAO N, Weng S, Liu Z, Xu H, et al
    CRISPR-Cas9 identifies growth-related subtypes of glioblastoma with therapeutical significance through cell line knockdown.
    BMC Cancer. 2023;23:749.
    PubMed     Abstract available
    
    
    
70. ZHONG K, Shi Y, Gao Y, Zhang H, et al
    First-line induction chemotherapy with high-dose methotrexate versus teniposide in patients with newly diagnosed primary central nervous system lymphoma: a retrospective, multicenter cohort study.
    BMC Cancer. 2023;23:746.
    PubMed     Abstract available
    
    
    
71. LI J, Guo Q, Xing R
    Construction and validation of an immune infiltration-related risk model for predicting prognosis and immunotherapy response in low grade glioma.
    BMC Cancer. 2023;23:727.
    PubMed     Abstract available
    
    
    July 2023
72. TAN Q, Wang Q, Jin S, Zhou F, et al
    Network Evolution Model-based prediction of tumor mutation burden from radiomic-clinical features in endometrial cancers.
    BMC Cancer. 2023;23:712.
    PubMed     Abstract available
    
    
    
73. CHIEN CH, Lai CC, Chuang JY, Chu JM, et al
    Role of SH3GLB1 in the regulation of CD133 expression in GBM cells.
    BMC Cancer. 2023;23:713.
    PubMed     Abstract available
    
    
    
74. WALTENBERGER M, Bernhardt D, Diehl C, Gempt J, et al
    Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiosurgery (SRS) to the resection cavity of brain metastases after surgical resection (SATURNUS): study protocol for a randomized phase III trial.
    BMC Cancer. 2023;23:709.
    PubMed     Abstract available
    
    
    
75. TAO R, Huang R, Yang J, Wang J, et al
    Comprehensive analysis of the clinical and biological significances of cholesterol metabolism in lower-grade gliomas.
    BMC Cancer. 2023;23:692.
    PubMed     Abstract available
    
    
    
76. YUEYANG M, Yaqin H, Guolian X, Wenjian Z, et al
    Glioma angiogenesis is boosted by ELK3 activating the HIF-1[Formula: see text]/VEGF-A signaling axis.
    BMC Cancer. 2023;23:662.
    PubMed     Abstract available
    
    
    June 2023
77. PENG Y, Liu H, Wu Q, Wang L, et al
    Integrated bioinformatics analysis and experimental validation reveal ISG20 as a novel prognostic indicator expressed on M2 macrophage in glioma.
    BMC Cancer. 2023;23:596.
    PubMed     Abstract available
    
    
    
78. XUE Z, Wang J, Wang Z, Liu J, et al
    SLC25A32 promotes malignant progression of glioblastoma by activating PI3K-AKT signaling pathway.
    BMC Cancer. 2023;23:589.
    PubMed     Abstract available
    
    
    
79. SUN S, Yang C, Wang K, Huang R, et al
    Molecular and clinical characterization of PTRF in glioma via 1,022 samples.
    BMC Cancer. 2023;23:551.
    PubMed     Abstract available
    
    
    
80. WEI L, Pan M, Jiang Q, Hu B, et al
    Eukaryotic initiation factor 4 A-3 promotes glioblastoma growth and invasion through the Notch1-dependent pathway.
    BMC Cancer. 2023;23:550.
    PubMed     Abstract available
    
    
    
81. FU M, Zhou Z, Huang X, Chen Z, et al
    Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map.
    BMC Cancer. 2023;23:544.
    PubMed     Abstract available
    
    
    
82. HAO Z, Huajun S, Zhen G, Yu X, et al
    AQP8 promotes glioma proliferation and growth, possibly through the ROS/PTEN/AKT signaling pathway.
    BMC Cancer. 2023;23:516.
    PubMed     Abstract available
    
    
    
83. BABAZADEH SM, Zolfaghari MR, Zargar M, Baesi K, et al
    Interleukin-24-mediated antitumor effects against human glioblastoma via upregulation of P38 MAPK and endogenous TRAIL-induced apoptosis and LC3-II activation-dependent autophagy.
    BMC Cancer. 2023;23:519.
    PubMed     Abstract available
    
    
    May 2023
84. AKANDA MR, Ahn EJ, Kim YJ, Salam SMA, et al
    Analysis of stromal PDGFR-beta and alpha-SMA expression and their clinical relevance in brain metastases of breast cancer patients.
    BMC Cancer. 2023;23:468.
    PubMed     Abstract available
    
    
    
85. CHEN Y, Ma F, Zhang Z, Guo Y, et al
    LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.
    BMC Cancer. 2023;23:455.
    PubMed     Abstract available
    
    
    
86. DUAN X, Yang B, Zhao C, Tie B, et al
    Prognostic value of preoperative hematological markers in patients with glioblastoma multiforme and construction of random survival forest model.
    BMC Cancer. 2023;23:432.
    PubMed     Abstract available
    
    
    
87. LIU ZY, Lan T, Tang F, He YZ, et al
    ZDHHC15 promotes glioma malignancy and acts as a novel prognostic biomarker for patients with glioma.
    BMC Cancer. 2023;23:420.
    PubMed     Abstract available
    
    
    
88. WANG X, Zhang H, Zhang M, Zhang X, et al
    Proteogenomic characterization of ferroptosis regulators reveals therapeutic potential in glioblastoma.
    BMC Cancer. 2023;23:415.
    PubMed     Abstract available
    
    
    
89. ZOU R, Zhong X, Liang K, Zhi C, et al
    Elevated LILRB1 expression predicts poor prognosis and is associated with tumor immune infiltration in patients with glioma.
    BMC Cancer. 2023;23:403.
    PubMed     Abstract available
    
    
    April 2023
90. THIVAT E, Casile M, Moreau J, Molnar I, et al
    Phase I/II study testing the combination of AGuIX nanoparticles with radiochemotherapy and concomitant temozolomide in patients with newly diagnosed glioblastoma (NANO-GBM trial protocol).
    BMC Cancer. 2023;23:344.
    PubMed     Abstract available
    
    
    
91. ZHOU T, Zhu S, Xiong Q, Gan J, et al
    Intrathecal chemotherapy combined with systemic therapy in patients with refractory leptomeningeal metastasis of non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2023;23:333.
    PubMed     Abstract available
    
    
    
92. KELLER KM, Koetsier J, Schild L, Amo-Addae V, et al
    The potential of PARP as a therapeutic target across pediatric solid malignancies.
    BMC Cancer. 2023;23:310.
    PubMed     Abstract available
    
    
    March 2023
93. WANG H, Xing R, Li M, Zhang M, et al
    Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.
    BMC Cancer. 2023;23:289.
    PubMed     Abstract available
    
    
    
94. CROUZEN JA, Petoukhova AL, Broekman MLD, Fiocco M, et al
    SAFESTEREO: phase II randomized trial to compare stereotactic radiosurgery with fractionated stereotactic radiosurgery for brain metastases.
    BMC Cancer. 2023;23:273.
    PubMed     Abstract available
    
    
    
95. KING AL, Acquaye-Mallory AA, Vera E, Mendoza T, et al
    Feasibility and preliminary efficacy of a virtual reality intervention targeting distress and anxiety in primary brain tumor patients at the time of clinical evaluation: Study protocol for a phase 2 clinical trial.
    BMC Cancer. 2023;23:262.
    PubMed     Abstract available
    
    
    
96. LIU X, Li Z, Sun J, Zhang Z, et al
    Interaction between PD-L1 and soluble VEGFR1 in glioblastoma-educated macrophages.
    BMC Cancer. 2023;23:259.
    PubMed     Abstract available
    
    
    
97. ZHANG M, Liu X, Wang D, Ruan X, et al
    A novel cuproptosis-related gene signature to predict prognosis in Glioma.
    BMC Cancer. 2023;23:237.
    PubMed     Abstract available
    
    
    
98. CAIN SA, Pope B, Mangiola S, Mantamadiotis T, et al
    Somatic mutation landscape in a cohort of meningiomas that have undergone grade progression.
    BMC Cancer. 2023;23:216.
    PubMed     Abstract available
    
    
    
99. XU Z, Hao X, Wang Q, Yang K, et al
    Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy.
    BMC Cancer. 2023;23:206.
    PubMed     Abstract available
    
    
    
100. GEURTS BS, Battaglia TW, van Berge Henegouwen JM, Zeverijn LJ, et al
     Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours.
     BMC Cancer. 2023;23:205.
     PubMed     Abstract available
     
     
     February 2023
101. MADDISON K, Bowden NA, Graves MC, Tooney PA, et al
     Characteristics of vasculogenic mimicry and tumour to endothelial transdifferentiation in human glioblastoma: a systematic review.
     BMC Cancer. 2023;23:185.
     PubMed     Abstract available
     
     
     
102. QUESNEL A, Coles N, Angione C, Dey P, et al
     Glycosylation spectral signatures for glioma grade discrimination using Raman spectroscopy.
     BMC Cancer. 2023;23:174.
     PubMed     Abstract available
     
     
     
103. ZHU H, Tan J, Pan X, Ouyang H, et al
     HELLPAR/RRM2 axis related to HMMR as novel prognostic biomarker in gliomas.
     BMC Cancer. 2023;23:125.
     PubMed     Abstract available
     
     
     
104. ZHU X, Chen D, Sun Y, Yang S, et al
     LncRNA WEE2-AS1 is a diagnostic biomarker that predicts poor prognoses in patients with glioma.
     BMC Cancer. 2023;23:120.
     PubMed     Abstract available
     
     
     January 2023
105. DAI L, Guo X, Xing Z, Tao Y, et al
     Multi-omics analyses of CD276 in pan-cancer reveals its clinical prognostic value in glioblastoma and other major cancer types.
     BMC Cancer. 2023;23:102.
     PubMed     Abstract available
     
     
     
106. ZHANG GT, Liu Q, Zuo FX, Liu HJ, et al
     Clinical and genomic features in patients with second primary glioblastoma following first primary renal cell carcinoma.
     BMC Cancer. 2023;23:104.
     PubMed     Abstract available
     
     
     
107. LILJEDAHL E, Konradsson E, Gustafsson E, Jonsson KF, et al
     Combined anti-C1-INH and radiotherapy against glioblastoma.
     BMC Cancer. 2023;23:106.
     PubMed     Abstract available
     
     
     
108. LIEDE A, Sebby W, Miriyala AKR, Potluri R, et al
     Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States.
     BMC Cancer. 2023;23:78.
     PubMed     Abstract available
     
     
     
109. LI L, Zhang C, Wang Z, Wang Y, et al
     Development of an integrated predictive model for postoperative glioma-related epilepsy using gene-signature and clinical data.
     BMC Cancer. 2023;23:42.
     PubMed     Abstract available
     
     
     
110. WANG X, Li X, Wu Y, Hong J, et al
     The prognostic significance of tumor-associated neutrophils and circulating neutrophils in glioblastoma (WHO CNS5 classification).
     BMC Cancer. 2023;23:20.
     PubMed     Abstract available
     
     
     
111. LI C, Xi S, Chen Y, Guo C, et al
     Clinical significance of histopathological features of paired recurrent gliomas: a cohort study from a single cancer center.
     BMC Cancer. 2023;23:8.
     PubMed     Abstract available
     
     
     December 2022
112. DAS S, Faruqi S, Nordal R, Starreveld Y, et al
     A phase III, multicenter, randomized controlled trial of preoperative versus postoperative stereotactic radiosurgery for patients with surgically resectable brain metastases.
     BMC Cancer. 2022;22:1368.
     PubMed     Abstract available
     
     
     
113. ZHU Y, Teng Y, Xu S, Xu Y, et al
     Eczema as a protective factor for brain cancer: a meta-analysis.
     BMC Cancer. 2022;22:1360.
     PubMed     Abstract available
     
     
     
114. PENG D, Liang P, Zhong C, Xu P, et al
     Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study.
     BMC Cancer. 2022;22:1323.
     PubMed     Abstract available
     
     
     
115. ZWAIG M, Baguette A, Hu B, Johnston M, et al
     Detection and genomic analysis of BRAF fusions in Juvenile Pilocytic Astrocytoma through the combination and integration of multi-omic data.
     BMC Cancer. 2022;22:1297.
     PubMed     Abstract available
     
     
     
116. SHANG K, Huang H, Xu Y, Liu Y, et al
     Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non-small-cell lung cancer with an EGFR/TP53 co-mutation.
     BMC Cancer. 2022;22:1295.
     PubMed     Abstract available
     
     
     
117. ZHAO S, Ji W, Shen Y, Fan Y, et al
     Expression of hub genes of endothelial cells in glioblastoma-A prognostic model for GBM patients integrating single-cell RNA sequencing and bulk RNA sequencing.
     BMC Cancer. 2022;22:1274.
     PubMed     Abstract available
     
     
     
118. TOMITA N, Ishiyama H, Makita C, Ohshima Y, et al
     Daily irradiation versus irradiation at two- to three-day intervals in stereotactic radiotherapy for patients with 1-5 brain metastases: study protocol for a multicenter open-label randomized phase II trial.
     BMC Cancer. 2022;22:1259.
     PubMed     Abstract available
     
     
     November 2022
119. KIM JW, Park SH, Choi SA, Kim SK, et al
     Molecular subgrouping of medulloblastoma in pediatric population using the NanoString assay and comparison with immunohistochemistry methods.
     BMC Cancer. 2022;22:1221.
     PubMed     Abstract available
     
     
     
120. LIU X, Yang J, Li H, Wang Q, et al
     Quantifying substantial carcinogenesis of genetic and environmental factors from measurement error in the number of stem cell divisions.
     BMC Cancer. 2022;22:1194.
     PubMed     Abstract available
     
     
     
121. ZHANG Y, Wang X, Shi M, Song Y, et al
     Programmed death ligand 1 and tumor-infiltrating CD8(+) T lymphocytes are associated with the clinical features in meningioma.
     BMC Cancer. 2022;22:1171.
     PubMed     Abstract available
     
     
     October 2022
122. GALLITTO M, Savacool M, Lee A, Wang TJC, et al
     Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma.
     BMC Cancer. 2022;22:1095.
     PubMed     Abstract available
     
     
     September 2022
123. CHEN Z, Zhou L, Zhao M, Cao K, et al
     Real-world analysis of different intracranial radiation therapies in non-small cell lung cancer patients with 1-4 brain metastases.
     BMC Cancer. 2022;22:1010.
     PubMed     Abstract available
     
     
     
124. CHOI JM, Lim SH, Liu ZP, Lee TK, et al
     Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model.
     BMC Cancer. 2022;22:986.
     PubMed     Abstract available
     
     
     
125. TU Z, Ji Q, Han Q, Long X, et al
     Intrinsic immune evasion patterns predict temozolomide sensitivity and immunotherapy response in lower-grade gliomas.
     BMC Cancer. 2022;22:973.
     PubMed     Abstract available
     
     
     
126. WENDLER J, Fox CP, Valk E, Steinheber C, et al
     Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
     BMC Cancer. 2022;22:971.
     PubMed     Abstract available
     
     
     August 2022
127. HUANG Y, Ouyang F, Yang F, Zhang N, et al
     The expression of Hexokinase 2 and its hub genes are correlated with the prognosis in glioma.
     BMC Cancer. 2022;22:900.
     PubMed     Abstract available
     
     
     
128. YU H, Gong M, Qi J, Zhao C, et al
     Systematic transcriptome profiling of pyroptosis related signature for predicting prognosis and immune landscape in lower grade glioma.
     BMC Cancer. 2022;22:885.
     PubMed     Abstract available
     
     
     
129. JIANG L, Yang J, Xu Q, Lv K, et al
     Machine learning for the micropeptide encoded by LINC02381 regulates ferroptosis through the glucose transporter SLC2A10 in glioblastoma.
     BMC Cancer. 2022;22:882.
     PubMed     Abstract available
     
     
     
130. SCHULZ JA, Rodgers LT, Kryscio RJ, Hartz AMS, et al
     Characterization and comparison of human glioblastoma models.
     BMC Cancer. 2022;22:844.
     PubMed     Abstract available
     
     
     
131. ROY C, Avril S, Legendre C, Lelievre B, et al
     A role for ceruloplasmin in the control of human glioblastoma cell responses to radiation.
     BMC Cancer. 2022;22:843.
     PubMed     Abstract available
     
     
     July 2022
132. GUAN Y, Pan M, Yang J, Lu Q, et al
     A phase II open label, single arm study of hypofractionated stereotactic radiotherapy with chemoradiotherapy using intensity-modulated radiotherapy for newly diagnosed glioblastoma after surgery: the HSCK-010 trial protocol.
     BMC Cancer. 2022;22:827.
     PubMed     Abstract available
     
     
     
133. YU J, Gao G, Wei X, Wang Y, et al
     TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma.
     BMC Cancer. 2022;22:786.
     PubMed     Abstract available
     
     
     
134. ABUHAMED J, Nikkila A, Raitanen J, Alimam W, et al
     Incidence trends of childhood central nervous system tumors in Finland 1990-2017.
     BMC Cancer. 2022;22:784.
     PubMed     Abstract available
     
     
     
135. WU X, Li C, Wang Z, Zhang Y, et al
     A bioinformatic analysis study of m(7)G regulator-mediated methylation modification patterns and tumor microenvironment infiltration in glioblastoma.
     BMC Cancer. 2022;22:729.
     PubMed     Abstract available
     
     
     June 2022
136. LI JD, Farah AA, Huang ZG, Zhai GQ, et al
     Clinical significance and potential regulatory mechanism of overexpression of pituitary tumor-transforming gene transcription factor in bladder cancer.
     BMC Cancer. 2022;22:713.
     PubMed     Abstract available
     
     
     
137. WANG J, Qiu X, Huang J, Zhuo Z, et al
     Development and validation of a novel mitophagy-related gene prognostic signature for glioblastoma multiforme.
     BMC Cancer. 2022;22:644.
     PubMed     Abstract available
     
     
     
138. WICK A, Sander A, Koch M, Bendszus M, et al
     Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
     BMC Cancer. 2022;22:645.
     PubMed     Abstract available
     
     
     
139. MALA U, Baral TK, Somasundaram K
     Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene.
     BMC Cancer. 2022;22:642.
     PubMed     Abstract available
     
     
     
140. DING MR, Qu YJ, Peng X, Chen JF, et al
     Pyroptosis-related prognosis model, immunocyte infiltration characterization, and competing endogenous RNA network of glioblastoma.
     BMC Cancer. 2022;22:611.
     PubMed     Abstract available
     
     
     
141. GATELY L, Drummond K, Rosenthal M, Harrup R, et al
     Beyond standard data collection - the promise and potential of BRAIN (Brain tumour Registry Australia INnovation and translation registry).
     BMC Cancer. 2022;22:604.
     PubMed     Abstract available
     
     
     May 2022
142. YANG H, Wen L, Pan Y, Shan C, et al
     Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
     BMC Cancer. 2022;22:580.
     PubMed     Abstract available
     
     
     
143. XU X, Yuan H, Pan J, Chen W, et al
     The identification of miRNA and mRNA expression profiles associated with pediatric atypical teratoid/rhabdoid tumor.
     BMC Cancer. 2022;22:499.
     PubMed     Abstract available
     
     
     
144. FISCHER GF, Brugge D, Andratschke N, Baumert BG, et al
     Postoperative radiotherapy for meningiomas - a decision-making analysis.
     BMC Cancer. 2022;22:492.
     PubMed     Abstract available
     
     
     April 2022
145. KOOPAIE M, Ghafourian M, Manifar S, Younespour S, et al
     Evaluation of CSTB and DMBT1 expression in saliva of gastric cancer patients and controls.
     BMC Cancer. 2022;22:473.
     PubMed     Abstract available
     
     
     
146. LI J, Wang J, Ding Y, Zhao J, et al
     Prognostic biomarker SGSM1 and its correlation with immune infiltration in gliomas.
     BMC Cancer. 2022;22:466.
     PubMed     Abstract available
     
     
     
147. ZHANG J, Guo Z, Xie Q, Zhong C, et al
     Tryptophan hydroxylase 1 drives glioma progression by modulating the serotonin/L1CAM/NF-kappaB signaling pathway.
     BMC Cancer. 2022;22:457.
     PubMed     Abstract available
     
     
     
148. KLEINBERGER I, Sanders E, Staes K, Van Troys M, et al
     Innovative mouse models for the tumor suppressor activity of Protocadherin-10 isoforms.
     BMC Cancer. 2022;22:451.
     PubMed     Abstract available
     
     
     
149. ARUNACHALAM E, Rogers W, Simpson GR, Moller-Levet C, et al
     HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiforme.
     BMC Cancer. 2022;22:400.
     PubMed     Abstract available
     
     
     
150. WANG C, Liu C, Chen J, Jiang H, et al
     Effect of neoadjuvant iodine-125 brachytherapy upon resection of glioma.
     BMC Cancer. 2022;22:397.
     PubMed     Abstract available
     
     
     
151. BELANGER K, Ung TH, Damek D, Lillehei KO, et al
     Concomitant Temozolomide plus radiotherapy for high-grade and recurrent meningioma: a retrospective chart review.
     BMC Cancer. 2022;22:367.
     PubMed     Abstract available
     
     
     March 2022
152. RYDEN I, Thurin E, Carstam L, Smits A, et al
     Correction: Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study.
     BMC Cancer. 2022;22:350.
     PubMed    
     
     
     
153. SANDER C, Frydrychowicz C, Prasse G, Taubenheim S, et al
     The impact of neurological performance and volumetrics on overall survival in brain metastasis in colorectal cancer: a retrospective single-center case series.
     BMC Cancer. 2022;22:336.
     PubMed     Abstract available
     
     
     
154. HESSLER N, Junger ST, Meissner AK, Kocher M, et al
     Recurrent brain metastases: the role of resection of in a comprehensive multidisciplinary treatment setting.
     BMC Cancer. 2022;22:275.
     PubMed     Abstract available
     
     
     
155. EGGEN AC, Hospers GAP, Bosma I, Kramer MCA, et al
     Anti-tumor treatment and healthcare consumption near death in the era of novel treatment options for patients with melanoma brain metastases.
     BMC Cancer. 2022;22:247.
     PubMed     Abstract available
     
     
     
156. BI Y, Wu ZH, Cao F
     Prognostic value and immune relevancy of a combined autophagy-, apoptosis- and necrosis-related gene signature in glioblastoma.
     BMC Cancer. 2022;22:233.
     PubMed     Abstract available
     
     
     
157. PUHAKKA I, Kuitunen H, Jakala P, Sonkajarvi E, et al
     Primary central nervous system lymphoma high incidence and poor survival in Finnish population-based analysis.
     BMC Cancer. 2022;22:236.
     PubMed     Abstract available
     
     
     
158. LI C, Liu F, Sun L, Liu Z, et al
     Natural killer cell-related gene signature predicts malignancy of glioma and the survival of patients.
     BMC Cancer. 2022;22:230.
     PubMed     Abstract available
     
     
     February 2022
159. MOU Y, Zhang L, Liu Z, Song X, et al
     Abundant expression of ferroptosis-related SAT1 is related to unfavorable outcome and immune cell infiltration in low-grade glioma.
     BMC Cancer. 2022;22:215.
     PubMed     Abstract available
     
     
     
160. WANG X, Wang Y, Xie F, Song ZT, et al
     Norepinephrine promotes glioma cell migration through up-regulating the expression of Twist1.
     BMC Cancer. 2022;22:213.
     PubMed     Abstract available
     
     
     
161. FU J, Zeng J, Huang M, Liang S, et al
     Primary versus postoperative gamma knife radiosurgery for intracranial benign meningiomas: a matched cohort retrospective study.
     BMC Cancer. 2022;22:206.
     PubMed     Abstract available
     
     
     
162. ZENG Y, Guo T, Zhou Y, Zhao Y, et al
     Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.
     BMC Cancer. 2022;22:198.
     PubMed     Abstract available
     
     
     
163. ZHANG X, Wu Y, Sun X, Cui Q, et al
     The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
     BMC Cancer. 2022;22:190.
     PubMed     Abstract available
     
     
     
164. BUENO-MARTINEZ E, Lara-Almunia M, Rodriguez-Arias C, Otero-Rodriguez A, et al
     Polymorphisms in autophagy genes are genetic susceptibility factors in glioblastoma development.
     BMC Cancer. 2022;22:146.
     PubMed     Abstract available
     
     
     
165. TRIPATHI PH, Akhtar J, Arora J, Saran RK, et al
     Quantitative proteomic analysis of GnRH agonist treated GBM cell line LN229 revealed regulatory proteins inhibiting cancer cell proliferation.
     BMC Cancer. 2022;22:133.
     PubMed     Abstract available
     
     
     January 2022
166. WEI R, Zhao C, Li J, Yang F, et al
     Online calculator to predict early mortality in patient with surgically treated recurrent lower-grade glioma.
     BMC Cancer. 2022;22:114.
     PubMed     Abstract available
     
     
     
167. MAO XG, Xue XY, Wang L, Lin W, et al
     Deep learning identified glioblastoma subtypes based on internal genomic expression ranks.
     BMC Cancer. 2022;22:86.
     PubMed     Abstract available
     
     
     
168. REN J, Zhang X, Cao J, Tian J, et al
     Radiosynthesis of a novel antisense imaging probe targeting LncRNA HOTAIR in malignant glioma.
     BMC Cancer. 2022;22:79.
     PubMed     Abstract available
     
     
     
169. SCHAFF LR, Lobbous M, Carlow D, Schofield R, et al
     Routine use of low-dose glucarpidase following high-dose methotrexate in adult patients with CNS lymphoma: an open-label, multi-center phase I study.
     BMC Cancer. 2022;22:60.
     PubMed     Abstract available
     
     
     
170. HOSEINI B, Rahmatinejad Z, Goshayeshi L, Bergquist R, et al
     Colorectal Cancer in North-Eastern Iran: a retrospective, comparative study of early-onset and late-onset cases based on data from the Iranian hereditary colorectal cancer registry.
     BMC Cancer. 2022;22:48.
     PubMed     Abstract available
     
     
     
171. ALVAREZ-TORRES MDM, Fuster-Garcia E, Juan-Albarracin J, Reynes G, et al
     Local detection of microvessels in IDH-wildtype glioblastoma using relative cerebral blood volume: an imaging marker useful for astrocytoma grade 4 classification.
     BMC Cancer. 2022;22:40.
     PubMed     Abstract available
     
     
     December 2021
172. RAYMOND P, Klein M, Cuny T, Klein O, et al
     High prevalence of anterior pituitary deficiencies after cranial radiation therapy for skull base meningiomas.
     BMC Cancer. 2021;21:1346.
     PubMed     Abstract available
     
     
     
173. ZHANG M, Cheng Y, Xue Z, Sun Q, et al
     A novel pyroptosis-related gene signature predicts the prognosis of glioma through immune infiltration.
     BMC Cancer. 2021;21:1311.
     PubMed     Abstract available
     
     
     November 2021
174. MACHARIA LW, Muriithi W, Heming CP, Nyaga DK, et al
     The genotypic and phenotypic impact of hypoxia microenvironment on glioblastoma cell lines.
     BMC Cancer. 2021;21:1248.
     PubMed     Abstract available
     
     
     
175. POON MTC, Bruce M, Simpson JE, Hannan CJ, et al
     Temozolomide sensitivity of malignant glioma cell lines - a systematic review assessing consistencies between in vitro studies.
     BMC Cancer. 2021;21:1240.
     PubMed     Abstract available
     
     
     
176. WEN J, Rusch M, Brady SW, Shao Y, et al
     The landscape of coding RNA editing events in pediatric cancer.
     BMC Cancer. 2021;21:1233.
     PubMed     Abstract available
     
     
     
177. XIE H, Yuan C, Ding XH, Li JJ, et al
     Identification of key genes and pathways associated with resting mast cells in meningioma.
     BMC Cancer. 2021;21:1209.
     PubMed     Abstract available
     
     
     
178. DJUZENOVA CS, Fischer T, Katzer A, Sisario D, et al
     Opposite effects of the triple target (DNA-PK/PI3K/mTOR) inhibitor PI-103 on the radiation sensitivity of glioblastoma cell lines proficient and deficient in DNA-PKcs.
     BMC Cancer. 2021;21:1201.
     PubMed     Abstract available
     
     
     
179. SU X, Yang Y, Yang Q, Pang B, et al
     NOX4-derived ROS-induced overexpression of FOXM1 regulates aerobic glycolysis in glioblastoma.
     BMC Cancer. 2021;21:1181.
     PubMed     Abstract available
     
     
     
180. XIE Y, Gong C, Zhang J, Wang L, et al
     Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
     BMC Cancer. 2021;21:1174.
     PubMed     Abstract available
     
     
     October 2021
181. TONNEAU M, Mouttet-Audouard R, Le Tinier F, Mirabel X, et al
     Stereotactic body radiotherapy for intramedullary metastases: a retrospective series at the Oscar Lambret center and a systematic review.
     BMC Cancer. 2021;21:1168.
     PubMed     Abstract available
     
     
     
182. ARAKAWA Y, Sasaki K, Mineharu Y, Uto M, et al
     A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII).
     BMC Cancer. 2021;21:1105.
     PubMed     Abstract available
     
     
     
183. KEMMERER CL, Schittenhelm J, Dubois E, Neumann L, et al
     Cerebrospinal fluid cytokine levels are associated with macrophage infiltration into tumor tissues of glioma patients.
     BMC Cancer. 2021;21:1108.
     PubMed     Abstract available
     
     
     
184. LIU R, Dai W, Wu A, Li Y, et al
     CircCDC45 promotes the malignant progression of glioblastoma by modulating the miR-485-5p/CSF-1 axis.
     BMC Cancer. 2021;21:1090.
     PubMed     Abstract available
     
     
     September 2021
185. CHENG S, Yang L, Dai X, Wang J, et al
     The risk and prognostic factors for brain metastases in esophageal cancer patients: an analysis of the SEER database.
     BMC Cancer. 2021;21:1057.
     PubMed     Abstract available
     
     
     
186. MAKINO Y, Arakawa Y, Yoshioka E, Shofuda T, et al
     Infrequent RAS mutation is not associated with specific histological phenotype in gliomas.
     BMC Cancer. 2021;21:1025.
     PubMed     Abstract available
     
     
     
187. TYLDESLEY-MARSHALL N, Greenfield S, Neilson SJ, English M, et al
     The role of Magnetic Resonance Images (MRIs) in coping for patients with brain tumours and their parents: a qualitative study.
     BMC Cancer. 2021;21:1013.
     PubMed     Abstract available
     
     
     
188. MIKIC N, Poulsen FR, Kristoffersen KB, Laursen RJ, et al
     Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: a phase 2, multi-center, randomized, prospective, interventional trial.
     BMC Cancer. 2021;21:1010.
     PubMed     Abstract available
     
     
     August 2021
189. HACKSHAW MD, Danysh HE, Henderson M, Wang E, et al
     Prognostic factors of brain metastasis and survival among HER2-positive metastatic breast cancer patients: a systematic literature review.
     BMC Cancer. 2021;21:967.
     PubMed     Abstract available
     
     
     
190. LI Y, Guo D
     Genome-wide profiling of alternative splicing in glioblastoma and their clinical value.
     BMC Cancer. 2021;21:958.
     PubMed     Abstract available
     
     
     
191. KIM YJ, Oh H, Lee SJ, Kim KM, et al
     Prognostic significance of the postoperative prognostic nutritional index in patients with glioblastoma: a retrospective study.
     BMC Cancer. 2021;21:942.
     PubMed     Abstract available
     
     
     
192. XIAO J, Xu L, Ding Y, Wang W, et al
     Does post-operative radiotherapy improve the treatment outcomes of intracranial hemangiopericytoma? A retrospective study.
     BMC Cancer. 2021;21:915.
     PubMed     Abstract available
     
     
     July 2021
193. WANG X, Cai J, Zeng Z, Liu A, et al
     Efficacy of osimertinib for preventing leptomeningeal metastasis derived from advanced EGFR-mutated non-small cell lung cancer: a propensity-matched retrospective study.
     BMC Cancer. 2021;21:873.
     PubMed     Abstract available
     
     
     
194. GINZAC A, Dupic G, Brun L, Molnar I, et al
     Preoperative stereotactic radiosurgery for brain metastases: the STEP study protocol for a multicentre, prospective, phase-II trial.
     BMC Cancer. 2021;21:864.
     PubMed     Abstract available
     
     
     
195. ASANO K, Fumoto T, Matsuzaka M, Hasegawa S, et al
     Combination chemoradiotherapy with temozolomide, vincristine, and interferon-beta might improve outcomes regardless of O6-methyl-guanine-DNA-methyltransferase (MGMT) promoter methylation status in newly glioblastoma.
     BMC Cancer. 2021;21:867.
     PubMed     Abstract available
     
     
     
196. SYAFRUDDIN SE, Nazarie WFWM, Moidu NA, Soon BH, et al
     Integration of RNA-Seq and proteomics data identifies glioblastoma multiforme surfaceome signature.
     BMC Cancer. 2021;21:850.
     PubMed     Abstract available
     
     
     
197. HUANG T, Chen Y, Zeng Y, Xu C, et al
     Long non-coding RNA PSMA3-AS1 promotes glioma progression through modulating the miR-411-3p/HOXA10 pathway.
     BMC Cancer. 2021;21:844.
     PubMed     Abstract available
     
     
     
198. ZHANG F, He Q, Luo G, Long Y, et al
     The combination of (13)N-ammonia and (11)C-methionine in differentiation of residual/recurrent pituitary adenoma from the pituitary gland remnant after trans-sphenoidal Adenomectomy.
     BMC Cancer. 2021;21:837.
     PubMed     Abstract available
     
     
     
199. SHEN H, Deng G, Chen Q, Qian J, et al
     The incidence, risk factors and predictive nomograms for early death of lung cancer with synchronous brain metastasis: a retrospective study in the SEER database.
     BMC Cancer. 2021;21:825.
     PubMed     Abstract available
     
     
     June 2021
200. SCHEICHEL F, Marhold F, Pinggera D, Kiesel B, et al
     Influence of preoperative corticosteroid treatment on rate of diagnostic surgeries in primary central nervous system lymphoma: a multicenter retrospective study.
     BMC Cancer. 2021;21:754.
     PubMed     Abstract available
     
     
     
201. LU J, Peng Y, Huang R, Feng Z, et al
     Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade glioma.
     BMC Cancer. 2021;21:723.
     PubMed     Abstract available
     
     
     
202. TU Z, Xiong H, Qiu Y, Li G, et al
     Limited recurrence distance of glioblastoma under modern radiotherapy era.
     BMC Cancer. 2021;21:720.
     PubMed     Abstract available
     
     
     
203. ZHU W, Zhao H, Xu F, Huang B, et al
     The lipid-lowering drug fenofibrate combined with si-HOTAIR can effectively inhibit the proliferation of gliomas.
     BMC Cancer. 2021;21:664.
     PubMed     Abstract available
     
     
     
204. MOON HH, Kim HS, Park JE, Kim YH, et al
     Refinement of response assessment in neuro-oncology (RANO) using non-enhancing lesion type and contrast enhancement evolution pattern in IDH wild-type glioblastomas.
     BMC Cancer. 2021;21:654.
     PubMed     Abstract available
     
     
     May 2021
205. SHAN Q, Shi J, Wang X, Guo J, et al
     A new nomogram and risk classification system for predicting survival in small cell lung cancer patients diagnosed with brain metastasis: a large population-based study.
     BMC Cancer. 2021;21:640.
     PubMed     Abstract available
     
     
     
206. ZHU J, Wang H, Sun Q, Ji X, et al
     Correction to: Nrf2 is required to maintain the self-renewal of glioma stem cells.
     BMC Cancer. 2021;21:582.
     PubMed    
     
     
     
207. MILLS MN, Naz A, Thawani C, Walker C, et al
     Capecitabine and stereotactic radiation in the management of breast cancer brain metastases.
     BMC Cancer. 2021;21:552.
     PubMed     Abstract available
     
     
     
208. MAJCHRZAK-CELINSKA A, Misiorek JO, Kruhlenia N, Przybyl L, et al
     COXIBs and 2,5-dimethylcelecoxib counteract the hyperactivated Wnt/beta-catenin pathway and COX-2/PGE2/EP4 signaling in glioblastoma cells.
     BMC Cancer. 2021;21:493.
     PubMed     Abstract available
     
     
     April 2021
209. YAMAMURA J, Kamigaki S, Fujita J, Osato H, et al
     New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients.
     BMC Cancer. 2021;21:476.
     PubMed     Abstract available
     
     
     
210. XU B, Huo Z, Huang H, Ji W, et al
     The expression and prognostic value of the epidermal growth factor receptor family in glioma.
     BMC Cancer. 2021;21:451.
     PubMed     Abstract available
     
     
     
211. AMIN S, Baine M, Meza J, Lin C, et al
     The impact of treatment facility type on the survival of brain metastases patients regardless of the primary cancer type.
     BMC Cancer. 2021;21:387.
     PubMed     Abstract available
     
     
     
212. RADES D, Witteler J, Olbrich D, Trillenberg P, et al
     A prospective interventional study evaluating seizure activity during a radiotherapy course for high-grade gliomas (SURF-ROGG).
     BMC Cancer. 2021;21:386.
     PubMed     Abstract available
     
     
     March 2021
213. KUO CS, Tung PH, Huang AC, Wang CC, et al
     A retrospective study of alectinib versus ceritinib in patients with advanced non-small-cell lung cancer of anaplastic lymphoma kinase fusion in whom crizotinib treatment failed.
     BMC Cancer. 2021;21:309.
     PubMed     Abstract available
     
     
     
214. XI J, Hassan B, Katumba RGN, Khaddour K, et al
     The predictive value of absolute lymphocyte counts on tumor progression and pseudoprogression in patients with glioblastoma.
     BMC Cancer. 2021;21:285.
     PubMed     Abstract available
     
     
     
215. KIANG KM, Chan AA, Leung GK
     Secondary gliosarcoma: the clinicopathological features and the development of a patient-derived xenograft model of gliosarcoma.
     BMC Cancer. 2021;21:265.
     PubMed     Abstract available
     
     
     
216. ZHANG C, Liu H, Xu P, Tan Y, et al
     Identification and validation of a five-lncRNA prognostic signature related to Glioma using bioinformatics analysis.
     BMC Cancer. 2021;21:251.
     PubMed     Abstract available
     
     
     
217. RYDEN I, Thurin E, Carstam L, Smits A, et al
     Psychotropic and anti-epileptic drug use, before and after surgery, among patients with low-grade glioma: a nationwide matched cohort study.
     BMC Cancer. 2021;21:248.
     PubMed     Abstract available
     
     
     
218. MILLS MN, Walker C, Thawani C, Naz A, et al
     Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases.
     BMC Cancer. 2021;21:223.
     PubMed     Abstract available
     
     
     
219. MASALHA W, Daka K, Woerner J, Pompe N, et al
     Metabolic alterations in meningioma reflect the clinical course.
     BMC Cancer. 2021;21:211.
     PubMed     Abstract available
     
     
     February 2021
220. ZHANG Y, Zou D, Yin J, Zhang L, et al
     Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
     BMC Cancer. 2021;21:183.
     PubMed     Abstract available
     
     
     
221. KHAN M, Zhao Z, Arooj S, Liao G, et al
     Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis.
     BMC Cancer. 2021;21:167.
     PubMed     Abstract available
     
     
     
222. KEOGH RJ, Aslam R, Hennessy MA, Coyne Z, et al
     One year of procarbazine lomustine and vincristine is poorly tolerated in low grade glioma: a real world experience in a national neuro-oncology centre.
     BMC Cancer. 2021;21:140.
     PubMed     Abstract available
     
     
     
223. GUAN Y, Xiong J, Pan M, Shi W, et al
     Safety and efficacy of Hypofractionated stereotactic radiosurgery for high-grade Gliomas at first recurrence: a single-center experience.
     BMC Cancer. 2021;21:123.
     PubMed     Abstract available
     
     
     January 2021
224. LIU G, Liu D, Huang J, Li J, et al
     Comprehensive analysis of ceRNA network related to lincRNA in glioblastoma and prediction of clinical prognosis.
     BMC Cancer. 2021;21:98.
     PubMed     Abstract available
     
     
     
225. LIU FM, Gao YF, Kong Y, Guan Y, et al
     The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET.
     BMC Cancer. 2021;21:83.
     PubMed     Abstract available
     
     
     
226. WEN J, Chen W, Zhu Y, Zhang P, et al
     Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis.
     BMC Cancer. 2021;21:81.
     PubMed     Abstract available
     
     
     
227. CHEN B, Chen C, Zhang Y, Xu J, et al
     Recent incidence trend of elderly patients with glioblastoma in the United States, 2000-2017.
     BMC Cancer. 2021;21:54.
     PubMed     Abstract available
     
     
     
228. WANG Y, Zhang Y, Hong Y, Zeng P, et al
     Advance directives and end-of-life care: knowledge and preferences of patients with brain Tumours from Anhui, China.
     BMC Cancer. 2021;21:25.
     PubMed     Abstract available
     
     
     December 2020
229. HIGGINS DMO, Caliva M, Schroeder M, Carlson B, et al
     Semaphorin 3A mediated brain tumor stem cell proliferation and invasion in EGFRviii mutant gliomas.
     BMC Cancer. 2020;20:1213.
     PubMed     Abstract available
     
     
     
230. COLLINS DC, Sundar R, Constantinidou A, Dolling D, et al
     Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease.
     BMC Cancer. 2020;20:1210.
     PubMed     Abstract available
     
     
     November 2020
231. YU X, Wang Y, Yuan Z, Yu H, et al
     Benefit of dosimetry distribution for patients with multiple brain metastases from non-small cell lung cancer by a Cyberknife stereotactic radiosurgery (SRS) system.
     BMC Cancer. 2020;20:1144.
     PubMed     Abstract available
     
     
     
232. LI X, Meng Y
     Analyses of metastasis-associated genes in IDH wild-type glioma.
     BMC Cancer. 2020;20:1114.
     PubMed     Abstract available
     
     
     
233. ZHU Z, Lan Y, Wang L, Ge J, et al
     A nuclear transport-related gene signature combined with IDH mutation and 1p/19q codeletion better predicts the prognosis of glioma patients.
     BMC Cancer. 2020;20:1072.
     PubMed     Abstract available
     
     
     
234. AFTAHY AK, Barz M, Krauss P, Liesche F, et al
     Intraventricular neuroepithelial tumors: surgical outcome, technical considerations and review of literature.
     BMC Cancer. 2020;20:1060.
     PubMed     Abstract available
     
     
     October 2020
235. CHIA BSH, Leong JY, Ong ALK, Lim C, et al
     Randomised prospective phase II trial in multiple brain metastases comparing outcomes between hippocampal avoidance whole brain radiotherapy with or without simultaneous integrated boost: HA-SIB-WBRT study protocol.
     BMC Cancer. 2020;20:1045.
     PubMed     Abstract available
     
     
     
236. DING X, Yang L, Geng X, Zou Y, et al
     CircRNAs as potential biomarkers for the clinicopathology and prognosis of glioma patients: a meta-analysis.
     BMC Cancer. 2020;20:1005.
     PubMed     Abstract available
     
     
     
237. GUENOLE M, Lucia F, Bourbonne V, Dissaux G, et al
     Impact of concomitant systemic treatments on toxicity and intracerebral response after stereotactic radiotherapy for brain metastases.
     BMC Cancer. 2020;20:991.
     PubMed     Abstract available
     
     
     
238. FENG J, Ouyang Y, Xu D, He Q, et al
     Genetic variants in MIR17HG affect the susceptibility and prognosis of glioma in a Chinese Han population.
     BMC Cancer. 2020;20:976.
     PubMed     Abstract available
     
     
     
239. HONG KT, Lee DH, Kim BK, An HY, et al
     Treatment outcome and long-term follow-up of central nervous system germ cell tumor using upfront chemotherapy with subsequent photon or proton radiation therapy: a single tertiary center experience of 127 patients.
     BMC Cancer. 2020;20:979.
     PubMed     Abstract available
     
     
     
240. BLECKMANN A, Kirchner B, Nietert M, Peeck M, et al
     Impact of pre-OP independence in patients with limited brain metastases on long-term survival.
     BMC Cancer. 2020;20:973.
     PubMed     Abstract available
     
     
     September 2020
241. WANG J, Tong L, Lin G, Wang H, et al
     Immunological and clinicopathological characteristics of C1RL in 2120 glioma patients.
     BMC Cancer. 2020;20:931.
     PubMed     Abstract available
     
     
     
242. DU F, Hou Q
     SNHG17 drives malignant behaviors in astrocytoma by targeting miR-876-5p/ERLIN2 axis.
     BMC Cancer. 2020;20:839.
     PubMed     Abstract available
     
     
     August 2020
243. COSTE A, Bailey HD, Kartal-Kaess M, Renella R, et al
     Parental occupational exposure to pesticides and risk of childhood cancer in Switzerland: a census-based cohort study.
     BMC Cancer. 2020;20:819.
     PubMed     Abstract available
     
     
     
244. HEILAND DH, Ohle R, Cipriani D, Franco P, et al
     Characterization of longitudinal transformation of T2-hyperintensity in oligodendroglioma.
     BMC Cancer. 2020;20:818.
     PubMed     Abstract available
     
     
     July 2020
245. LOCSEI Z, Farkas R, Borbasne Farkas K, Sebestyen K, et al
     Assessment of the results and hematological side effects of 3D conformal and IMRT/ARC therapies delivered during craniospinal irradiation of childhood tumors with a follow-up period of five years.
     BMC Cancer. 2020;20:702.
     PubMed     Abstract available
     
     
     
246. ZHAO Y, He JY, Cui JZ, Meng ZQ, et al
     Detection of genes mutations in cerebrospinal fluid circulating tumor DNA from neoplastic meningitis patients using next generation sequencing.
     BMC Cancer. 2020;20:690.
     PubMed     Abstract available
     
     
     
247. LIN J, Yu L, Fu Y, Chen H, et al
     A refractory case of CDK4-amplified spinal astrocytoma achieving complete response upon treatment with a Palbociclib-based regimen:a case report.
     BMC Cancer. 2020;20:630.
     PubMed     Abstract available
     
     
     
248. MEZEI T, Hajdu M, Czigleczki G, Lotz G, et al
     Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review.
     BMC Cancer. 2020;20:615.
     PubMed     Abstract available
     
     
     June 2020
249. MEHTA P, Janssen S, Fahlbusch FB, Schmid SM, et al
     Sparing the hippocampus and the hypothalamic- pituitary region during whole brain radiotherapy: a volumetric modulated arc therapy planning study.
     BMC Cancer. 2020;20:610.
     PubMed     Abstract available
     
     
     
250. XU T, Zhang X, Zhang S, Liu C, et al
     Imaging features and prognostic value of (18)F-FDG PET/CT detection of soft-tissue metastasis from lung cancer: a retrospective study.
     BMC Cancer. 2020;20:596.
     PubMed     Abstract available
     
     
     
251. GROSU AL, Frings L, Bentsalo I, Oehlke O, et al
     Whole-brain irradiation with hippocampal sparing and dose escalation on metastases: neurocognitive testing and biological imaging (HIPPORAD) - a phase II prospective randomized multicenter trial (NOA-14, ARO 2015-3, DKTK-ROG).
     BMC Cancer. 2020;20:532.
     PubMed     Abstract available
     
     
     
252. DEVECKA M, Duma MN, Wilkens JJ, Kampfer S, et al
     Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting.
     BMC Cancer. 2020;20:501.
     PubMed     Abstract available
     
     
     May 2020
253. BUCKSCH K, Zachariae S, Aretz S, Buttner R, et al
     Cancer risks in Lynch syndrome, Lynch-like syndrome, and familial colorectal cancer type X: a prospective cohort study.
     BMC Cancer. 2020;20:460.
     PubMed     Abstract available
     
     
     
254. WAKUDA K, Yamaguchi H, Kenmotsu H, Fukuda M, et al
     A phase II study of Osimertinib for patients with radiotherapy-naive CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L).
     BMC Cancer. 2020;20:370.
     PubMed     Abstract available
     
     
     April 2020
255. FURUSE M, Kuwabara H, Ikeda N, Hattori Y, et al
     PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
     BMC Cancer. 2020;20:277.
     PubMed     Abstract available
     
     
     March 2020
256. NAWROCKI S, Sugajska A
     Study protocol: watchful observation of patients with limited small cell lung cancer instead of the PCI-prospective, multi-center one-arm study.
     BMC Cancer. 2020;20:231.
     PubMed     Abstract available
     
     
     February 2020
257. CHO I, Lee H, Yoon SE, Ryu KJ, et al
     Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
     BMC Cancer. 2020;20:120.
     PubMed     Abstract available
     
     
     
258. TREUTWEIN M, Steger F, Loeschel R, Koelbl O, et al
     The influence of radiotherapy techniques on the plan quality and on the risk of secondary tumors in patients with pituitary adenoma.
     BMC Cancer. 2020;20:88.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Neoplasms of the CNS is free of charge.